HOME >> BIOLOGY >> NEWS
Past experience of pheromones induces dominant courtship behavior in fruit flies

By investigating the interplay between pheromone signaling and behavior in fruit flies, researchers have begun to understand how an adult fly's earlier experience as a young individual can influence its behavior towards other flies as an adult. In particular, the researchers found that pheromone signals in the context of experience with adult flies can influence how young flies will behave once they reach maturity.

The work is reported by Jean-Francois Ferveur and colleagues at the Universite de Bourgogne, France, and the University of Manchester, United Kingdom.

When an adult male fruit fly encounters a young male fly, he will actively court the younger individual, sometimes becoming aggressive. These young males that have encountered older flies will go on to similarly dominate other adult males that had encountered only young flies--something in the early experience of the "dominant" flies makes them more aggressive. In the new work, researchers investigated exactly what it is about past experience of these flies that influences adult behavior. Clues caused the researchers to suspect that a key role was played by a chemical signal--a pheromone--carried by adult males during the early encounter.

To prove this, the researches used mutant flies that lack the normal adult pheromones, and they covered these pheromone-defective flies with a variety of other smells. The researchers were able to demonstrate that a male shows courtship dominance behavior over young males if he has been exposed to the smell of normal adult males during a critical period in his life--the first 24 hours. In fact, an encounter with a single adult male was sufficient to make males exhibit dominance behavior when they reached adulthood. The researchers found that, intriguingly, it was not enough for young males to smell these pheromones--the pheromones had to be carried by active adult males. The effect was so strong that males carried on exhibiting courtship dominance b
'"/>

Contact: Heidi Hardman
hhardman@cell.com
1-617-397-2879
Cell Press
10-Oct-2005


Page: 1 2

Related biology news :

1. Success rates for prostate cancer depend on experience of surgeon
2. Out-of-body experiences may be caused by arousal system disturbances in brain
3. Early family experience can reverse the effects of genes, UCLA psychologists report
4. Mothers who gain weight between pregnancies may experience pregnancy complications
5. Long-term changes in experience cause neurons to sprout new long-lasting connections
6. Brain differences could explain why males and females experience pain relief differently
7. People with near death experiences can differ in sleep-wake control
8. Just the expectation of a mirthful laughter experience boosts endorphins 27 percent, HGH 87 percent
9. When mice choose mates, experience counts
10. Women pregnant with girls experience more severe asthma symptoms
11. Penguin chicks exposed to human visitors experience spike in stress hormone

Post Your Comments:
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: